Auckland-based soft tissue regeneration company Aroa Biosurgery Limited (Aroa) is set to list on the Australian Securities Exchange (ASX) as part of an initial public offering (IPO) that will see it raise $45m from investors.Continue Reading
San Diego, U.S. Soft tissue repair company Aroa Biosurgery is stepping up to support clinicians and their patients who are battling to treat wounds amid disruption to many existing U.S. facilities for wound care due to COVID-19.
Aroa Vice President Commercial, Brad Adams says the company has opened an additional pathway for its clinicians and patients to maintain access to Endoform®, an extracellular matrix technology that is proven to help wounds heal faster.
Aroa Biosurgery is taking the appropriate precautions and measures amid a rapidly changing global picture for COVID-19 virus.
CEO Brian Ward said; “We extend our thoughts to everyone affected by COVID-19. Our priority is ensuring our employees, contractors and customers are safe and protected from the spread of the virus. We will continue to make any necessary changes, and monitor the potential impacts of COVID-19 on our employees, customers and overall business, daily. At this stage we are not experiencing significant disruption or impact to the underlying production and marketing operations of our business and we continue to have adequate stock levels in market.”